|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCR6 |
Gene summary for CCR6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCR6 | Gene ID | 1235 |
| Gene name | C-C motif chemokine receptor 6 | |
| Gene Alias | BN-1 | |
| Cytomap | 6q27 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P51684 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1235 | CCR6 | HCC1_Meng | Human | Liver | HCC | 3.48e-17 | 4.04e-02 | 0.0246 |
| 1235 | CCR6 | HCC1 | Human | Liver | HCC | 2.28e-18 | 1.33e+00 | 0.5336 |
| 1235 | CCR6 | HCC2 | Human | Liver | HCC | 5.72e-28 | 1.82e+00 | 0.5341 |
| 1235 | CCR6 | HCC5 | Human | Liver | HCC | 1.45e-29 | 1.73e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0032886 | Liver | HCC | regulation of microtubule-based process | 123/7958 | 240/18723 | 3.69e-03 | 1.64e-02 | 123 |
| GO:0002200 | Liver | HCC | somatic diversification of immune receptors | 44/7958 | 77/18723 | 6.70e-03 | 2.72e-02 | 44 |
| GO:0016445 | Liver | HCC | somatic diversification of immunoglobulins | 38/7958 | 67/18723 | 1.32e-02 | 4.73e-02 | 38 |
| GO:000166721 | Liver | HCC | ameboidal-type cell migration | 226/7958 | 475/18723 | 1.35e-02 | 4.81e-02 | 226 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Breast | ADJ |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Breast | Healthy |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Cervix | ADJ |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Cervix | Healthy |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Cervix | Precancer |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Endometrium | ADJ |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Endometrium | AEH |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Endometrium | EEC |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | GC | ADJ |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | GC | GC |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | HNSCC | ADJ |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | HNSCC | OSCC |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | HNSCC | Precancer |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Lung | AAH |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Lung | MIAC |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Lung | Precancer |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Prostate | BPH |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Skin | cSCC |
| CCL20 | CCR6 | CCL20_CCR6 | CCL | Skin | SCCIS |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCR6 | SNV | Missense_Mutation | novel | c.969N>G | p.Phe323Leu | p.F323L | P51684 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCR6 | insertion | Nonsense_Mutation | novel | c.494_495insTTATTGATACTATTATATATGATATATGTGTGT | p.Lys165delinsAsnTyrTerTyrTyrTyrIleTerTyrMetCysVal | p.K165delinsNY*YYYI*YMCV | P51684 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| CCR6 | insertion | Frame_Shift_Ins | novel | c.216_217insGAAA | p.Phe73GlufsTer4 | p.F73Efs*4 | P51684 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CCR6 | insertion | In_Frame_Ins | novel | c.417_418insCTTGCCTCCTCTCTTTTTGCCCCTCTCATCAATAGA | p.Ile139_Ser140insLeuAlaSerSerLeuPheAlaProLeuIleAsnArg | p.I139_S140insLASSLFAPLINR | P51684 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| CCR6 | insertion | Frame_Shift_Ins | novel | c.126_127insCTTT | p.Gln43LeufsTer34 | p.Q43Lfs*34 | P51684 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| CCR6 | insertion | Nonsense_Mutation | novel | c.128_129insCACTTCTATAGATTTTGTTCAGTAAAATCTT | p.Gln43HisfsTer9 | p.Q43Hfs*9 | P51684 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| CCR6 | deletion | Frame_Shift_Del | novel | c.363delN | p.Gly123AlafsTer14 | p.G123Afs*14 | P51684 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| CCR6 | SNV | Missense_Mutation | novel | c.969N>G | p.Phe323Leu | p.F323L | P51684 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCR6 | SNV | Missense_Mutation | c.943N>T | p.Leu315Phe | p.L315F | P51684 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| CCR6 | SNV | Missense_Mutation | rs752574574 | c.830C>T | p.Thr277Met | p.T277M | P51684 | protein_coding | tolerated(0.08) | possibly_damaging(0.75) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1235 | CCR6 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, G PROTEIN COUPLED RECEPTOR | TRAIL | 12176034 | ||
| 1235 | CCR6 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, G PROTEIN COUPLED RECEPTOR | PYRIDINE-2-CARBOTHIOIC ACID PHENYLAMIDE | CHEMBL114544 | ||
| 1235 | CCR6 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, G PROTEIN COUPLED RECEPTOR | SJ000044511 | CHEMBL592124 | ||
| 1235 | CCR6 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, G PROTEIN COUPLED RECEPTOR | agonist | 135652054 | ||
| 1235 | CCR6 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, G PROTEIN COUPLED RECEPTOR | agonist | 135651668 | ||
| 1235 | CCR6 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, G PROTEIN COUPLED RECEPTOR | agonist | 178100550 | ||
| 1235 | CCR6 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, G PROTEIN COUPLED RECEPTOR | agonist | 178100546 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |